We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. The Administrator of personal data is STOCKTRADEIQ sp. z o.o., with its registered office in Poznan (61-625), at the following address: Czarna Rola 30 Street. Cookies policy here. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

  • Cookie
    cookieyes-consent
  • Duration
    1 year
  • Description
    CookieYes sets this cookie to remember users' consent preferences so that their preferences are respected on their subsequent visits to this site. It does not collect or store any personal information of the site visitors.
  • Cookie
    x-ms-cpim-csrf
  • Duration
    session
  • Description

    Inter-site request forgery token used to protect crSF. For more information, read the section Token falsification of requests between sites.

  • Cookie
    x-ms-cpim-sso:stocktradeiqauth.onmicrosoft.com_0
  • Duration
    session
  • Description

    Used to support single sign-on sessions. This cookie is set as persistent when the Keep me logged in option is enabled.

  • Cookie
    server-telemetry-{id}
  • Duration
    persistent
  • Description

    A value used by Microsoft for authorisation and authentication.

  • Cookie
    google_auto_fc_cmp_setting
  • Duration
    persistent
  • Description


    Stores the state of the User cookie for the current domain.

     

  • Cookie
    {id}-https://stocktradeiqauth.onmicrosoft.com/{id}
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    msal{id}.active-account
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-refreshtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-idtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    Microsoft Clarity
  • Duration
    1 year
  • Description

    Microsoft Clarity

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

  • Cookie
    isLightMode
  • Duration
    1 year
  • Description

    Defines the UI theme

  • Cookie
    userCultureData
  • Duration
    persistent
  • Description

     Stores information about the user's machine culture.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

  • Cookie
    _ga
  • Duration
    1 year 1 month 4 days
  • Description
    The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
  • Cookie
    _ga_*
  • Duration
    1 year 1 month 4 days
  • Description
    Google Analytics sets this cookie to store and count page views.
  • Cookie
    hotjar
  • Duration
    1 year 1 month 4 days
  • Description

    Analyzing users' behaviour in the website

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

  • Cookie
    __gpi
  • Duration
    1 year 24 days
  • Description
    Google Ads Service uses this cookie to collect information about from multiple websites for retargeting ads.
  • Cookie
    __gads
  • Duration
    1 year 24 days
  • Description

    The file, set by Google, is stored in the DoubleClick domain and tracks the number of times users view an ad, measures the success of the campaign and calculates its revenue. This cookie can only be read from the domain where it is set and does not track any data when browsing other sites.

  • Cookie
    goog:cached:topics
  • Duration
    persistent
  • Description

    It is used to record which adverts have been displayed to the User.

  • Cookie
    IDE
  • Duration
    year
  • Description

    Used by Google DoubleClick to record and report on the Website User's actions after viewing or clicking on an advertiser's ads in order to measure the effectiveness of the ad and present the User with targeted advertising.

  • Cookie
    google_experiment_mod44
  • Duration
    persistent
  • Description

    Used by Google Ad to experiment with the effectiveness of ads on websites using their services.

Powered by Cookieyes logo

    Get Diamond plan for FREE

    logo

    Pliant Therapeutics, Inc. (PLRX)

    Price:

    1.53 USD

    ( + 0.05 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    PLRX
    Name
    Pliant Therapeutics, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    1.530
    Market Cap
    93.924M
    Enterprise value
    786.298M
    Currency
    USD
    Ceo
    Bernard Coulie
    Full Time Employees
    171
    Website
    pliantrx.com
    Ipo Date
    2020-06-03
    City
    South San Francisco
    Address
    260 Littlefield Avenue

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    58.569B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Harmony Biosciences Holdings, Inc.

    VALUE SCORE:

    12

    Symbol
    HRMY
    Market Cap
    1.531B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Agios Pharmaceuticals, Inc.

    VALUE SCORE:

    12

    Symbol
    AGIO
    Market Cap
    2.453B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -0.454
    P/S
    41.376
    P/B
    0.427
    Debt/Equity
    0.136
    EV/FCF
    -0.217
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    16.352
    Earnings yield
    -2.204
    Debt/assets
    0.100
    FUNDAMENTALS
    Net debt/ebidta
    0.282
    Interest coverage
    -66.243
    Research And Developement To Revenue
    71.445
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.009
    Capex to revenue
    0.652
    Capex to depreciation
    0.785
    Return on tangible assets
    -0.690
    Debt to market cap
    0.320
    Piotroski Score
    3.000
    FUNDAMENTALS
    PEG
    -0.078
    P/CF
    -0.554
    P/FCF
    -0.550
    RoA %
    -69.027
    RoIC %
    -78.394
    Gross Profit Margin %
    -12.863
    Quick Ratio
    12.988
    Current Ratio
    12.988
    Net Profit Margin %
    -9.117k
    Net-Net
    3.002
    FUNDAMENTALS PER SHARE
    FCF per share
    -2.784
    Revenue per share
    0.037
    Net income per share
    -3.371
    Operating cash flow per share
    -2.760
    Free cash flow per share
    -2.784
    Cash per share
    4.282
    Book value per share
    3.585
    Tangible book value per share
    3.585
    Shareholders equity per share
    3.585
    Interest debt per share
    0.543
    TECHNICAL
    52 weeks high
    16.100
    52 weeks low
    1.100
    Current trading session High
    1.545
    Current trading session Low
    1.480
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -13.413
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.432
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.464
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    79.227
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -13.772
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -11.132
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    34.334
    DESCRIPTION

    Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

    NEWS
    https://images.financialmodelingprep.com/news/pliant-therapeutics-provides-corporate-update-and-reports-second-quarter-20250807.jpg
    Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

    globenewswire.com

    2025-08-07 16:05:00

    BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in integrin-based drug development, today provided a corporate update and reported second quarter 2025 financial results.

    https://images.financialmodelingprep.com/news/pliant-therapeutics-provides-update-on-beaconipf-20250627.jpg
    Pliant Therapeutics Provides Update on BEACON-IPF

    globenewswire.com

    2025-06-27 16:05:00

    Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF).

    https://images.financialmodelingprep.com/news/pliant-therapeutics-presents-clinical-and-preclinical-dataat-the-american-20250521.jpg
    Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

    globenewswire.com

    2025-05-21 16:03:00

    SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025.

    https://images.financialmodelingprep.com/news/pliant-therapeutics-provides-corporate-update-and-reports-first-quarter-20250508.jpg
    Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

    globenewswire.com

    2025-05-08 16:05:00

    Activities supporting the close out of BEACON-IPF continue; topline data  expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to  support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported first quarter 2025 financial results.

    https://images.financialmodelingprep.com/news/pliant-therapeutics-announces-strategic-realignment-of-workforce-and-operations-20250501.jpg
    Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

    globenewswire.com

    2025-05-01 16:05:00

    -  Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-20250425.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX

    globenewswire.com

    2025-04-25 12:01:00

    NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pliant-20250423.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

    accessnewswire.com

    2025-04-23 10:30:00

    NEW YORK, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investors-of-pliant-20250421.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

    globenewswire.com

    2025-04-21 17:26:00

    NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pliant-20250421.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

    globenewswire.com

    2025-04-21 16:21:00

    NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pliant-20250420.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

    accessnewswire.com

    2025-04-20 09:30:00

    NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pliant-20250418.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

    accessnewswire.com

    2025-04-18 13:45:00

    NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investors-of-pliant-20250417.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

    globenewswire.com

    2025-04-17 14:11:00

    NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pliant-20250416.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

    accessnewswire.com

    2025-04-16 13:45:00

    NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-pliant-20250415.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims - On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX

    accessnewswire.com

    2025-04-15 17:15:00

    NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ:PLRX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/pliant-therapt-plrx-upgraded-to-buy-heres-what-you-20250410.jpg
    PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should Know

    zacks.com

    2025-04-10 13:01:12

    PLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    https://images.financialmodelingprep.com/news/pliant-therapeutics-announces-upcoming-presentations-at-the-2025-american-20250407.jpg
    Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

    globenewswire.com

    2025-04-07 16:05:00

    SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16-21, 2025.